Parting Shots IVD Roundtable 510(k) Workshop

Slides:



Advertisements
Similar presentations
TAKE Solutions Enabling Business Efficiencies Ram Yeleswarapu President & CEO Analysts Meet Mumbai September 18, 2008.
Advertisements

Product Management & the FDA. Agenda/Scope What is different about managing products in a regulated industry? – Devices; Biologics; Pharma; Consumer goods;
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.
MOSCOW SCHOOL OF MANAGEMENT SKOLKOVO The Law Project Balance between the State and Business in state procurement.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Good Laboratory Practices (GLPs)
May May Win MA (TESOL) Lancaster University.  Choosing the course  Choosing modules  Study tips  Support from the university  Coursework  Dissertation.
Organizational Gaps in Reaching the “Desired State” Helen Winkle.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
Mark A. Del Vecchio Director, Regulatory and Clinical Affairs Digene Corporation How to Work with FDA: Industry Perspective IVD Roundtable/OIVD Workshop.
Case Study SummaryChallenges Boston Scientific needed medical translation in different areas in the medical field, including technical, legal and corporate.
Jeffrey Cossman, M.D. Standardizing the Evaluation of Diagnostics.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 An introduction to insurance 8 ways to save you money and reduce your risk.
1 Establishing an In Vitro Diagnostic (IVD) Claim Robert L. Becker, Jr, MD, PHD Director, Division of Immunology and Hematology Devices OIVD/CDRH/FDA.
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
First Annual Meeting. Project Development Teams: Concept and Example Scott C. Denne, M.D. Professor of Pediatrics Associate Director of the Indiana CTSI.
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
Diagnosing The Causes of Poor Pharmaceutical Systems Performance Marc J. Roberts Professor of Political Economy and Health Policy Harvard School of Public.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
ns/books/frey2011_fig1.2.gif.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
Global In Vitro Diagnostics (IVD) Industry 2016 Market Research Report
Regulatory Updates Health Sciences Authority Singapore
Research Compliance and Institutional Review Boards
Contract Research organizations
David Malek, VP Business Development
QV Training August 2017: Report-writing
U.S. FDA Center for Devices and Radiological Health Update
Benefit-Risk Guidance: Impact on FDA Decision-Making
Irena Prat and Josée Hansen World Health Organization
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Date of download: 10/20/2017 Copyright © ASME. All rights reserved.
FDA Perspective on Cardiovascular Device Development
Nicole Denjoy COCIR Secretary General
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Towards Good Read Across Practice
Introduction to Entrepreneurship: Leadership and Teams
Reproducibility of Research
The Current PMA Requirements
Industry Guidance on Part 21 Evaluation and Reporting
CDRH 2010 Strategic Priorities
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
US Early Feasibility Studies (EFS)
Innovation: A Priority for FDA
Designing An Effective Survey
Chapter 6 - Section 3/4.
Health and Safety related to new generation jobs
ICH Q9: Quality Risk Management
ICH Q9: Quality Risk Management
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Dr Peter Groves MD FRCP Consultant Cardiologist
Lessons Learned from the Mistakes of Others
Generic Medical Device Company (“MDC”)
Science for Peace and Security (SPS) Programme
Measuring transition from School to Labour Market
Evaluating the Relevance and Reliability of Sources
What do we mean by giftedness in science?
HUMAN COMPUTER INTERACTION. The main aims of the chapter are to: Explain the difference between good and poor interaction design. Describe what interaction.
Christleton Sixth Form: Bringing aspirations to life
Presentation transcript:

Parting Shots IVD Roundtable 510(k) Workshop Steven I. Gutman, MD, MBA Director Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) Workshop Product of the Industry IVD Round Table Good submissions are easy to review Good submissions are fast to review Bad submissions gum up the works

Clear Pathways Workshop Guidances Standards Articles Posting submissions

Three Kinds of Expertise Regulatory acumen Scientific acumen Statistical acumen In-house Contract

FDA Sound science Least burdensome Plain English Ask for the same Don’t assume

Companies Can Do a good job Quality control their work Use correct expertise

Common Deficiencies Unclear intended use Failure to link data to use Poor design -- lack of correlation to claim Failure to clarify how data generated and analyzed Insufficient data

Words of Advice Survey the field Make good choices Don’t assume more is more Utilize Pre-IDE process Bring in experts Don’t be afraid to question, appeal